CN101374807B - 用于抑制bcl蛋白与结合配偶体的相互作用的化合物和方法 - Google Patents
用于抑制bcl蛋白与结合配偶体的相互作用的化合物和方法 Download PDFInfo
- Publication number
- CN101374807B CN101374807B CN2006800528798A CN200680052879A CN101374807B CN 101374807 B CN101374807 B CN 101374807B CN 2006800528798 A CN2006800528798 A CN 2006800528798A CN 200680052879 A CN200680052879 A CN 200680052879A CN 101374807 B CN101374807 B CN 101374807B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- independently
- turn
- occurring
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- AKLMQABPYQTBDG-FQEVSTJZSA-N CN(C1)c2ccccc2C[C@@H]1NC(c1cc([N+]([O-])=O)cc(-c(cccc2C=O)c2OC)c1)=O Chemical compound CN(C1)c2ccccc2C[C@@H]1NC(c1cc([N+]([O-])=O)cc(-c(cccc2C=O)c2OC)c1)=O AKLMQABPYQTBDG-FQEVSTJZSA-N 0.000 description 1
- VPTSZLVPZCTAHZ-KZVJFYERSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1N Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1N VPTSZLVPZCTAHZ-KZVJFYERSA-N 0.000 description 1
- QCDVZGYFYRPFDY-ZVMOVJCVSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc([N+]([O-])=O)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CCC1)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc([N+]([O-])=O)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CCC1)=O QCDVZGYFYRPFDY-ZVMOVJCVSA-N 0.000 description 1
- RKPYIIHETAYKOQ-UVSCKVBMSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc2cccc(-c3cc(C(N[C@@H](Cc4ccccc4)CN(C)C)=O)cc(N(C)C)c3)c2OC)CC[C@@H]1O)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc2cccc(-c3cc(C(N[C@@H](Cc4ccccc4)CN(C)C)=O)cc(N(C)C)c3)c2OC)CC[C@@H]1O)=O RKPYIIHETAYKOQ-UVSCKVBMSA-N 0.000 description 1
- HANAZTFFNKVLFN-PPCPHDFISA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1NCCC1)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1NCCC1)=O HANAZTFFNKVLFN-PPCPHDFISA-N 0.000 description 1
- PDMAEZBOIJCMIK-FRTGSEIKSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1NCC[C@@H]1O)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1NCC[C@@H]1O)=O PDMAEZBOIJCMIK-FRTGSEIKSA-N 0.000 description 1
- 0 O[C@](CC*1)[C@]1C(O)=O Chemical compound O[C@](CC*1)[C@]1C(O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75098705P | 2005-12-16 | 2005-12-16 | |
| US60/750,987 | 2005-12-16 | ||
| PCT/US2006/047861 WO2007075387A1 (en) | 2005-12-16 | 2006-12-15 | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101374807A CN101374807A (zh) | 2009-02-25 |
| CN101374807B true CN101374807B (zh) | 2013-10-09 |
Family
ID=38024107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800528798A Expired - Fee Related CN101374807B (zh) | 2005-12-16 | 2006-12-15 | 用于抑制bcl蛋白与结合配偶体的相互作用的化合物和方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7745464B2 (enExample) |
| EP (1) | EP1973875B1 (enExample) |
| JP (1) | JP5341521B2 (enExample) |
| KR (1) | KR101373911B1 (enExample) |
| CN (1) | CN101374807B (enExample) |
| AR (1) | AR058855A1 (enExample) |
| AU (1) | AU2006329879B2 (enExample) |
| BR (1) | BRPI0619968A2 (enExample) |
| CA (1) | CA2633958C (enExample) |
| EC (1) | ECSP088607A (enExample) |
| ES (1) | ES2494765T3 (enExample) |
| IL (1) | IL192023A (enExample) |
| JO (1) | JO2918B1 (enExample) |
| MA (1) | MA30144B1 (enExample) |
| MX (1) | MX2008007687A (enExample) |
| MY (1) | MY153232A (enExample) |
| NO (1) | NO20083050L (enExample) |
| NZ (1) | NZ569660A (enExample) |
| PE (1) | PE20071033A1 (enExample) |
| RU (1) | RU2424230C2 (enExample) |
| SA (1) | SA06270462B1 (enExample) |
| SG (1) | SG170727A1 (enExample) |
| TN (1) | TNSN08258A1 (enExample) |
| TW (1) | TWI403320B (enExample) |
| WO (1) | WO2007075387A1 (enExample) |
| ZA (1) | ZA200805822B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| CN102015606B (zh) | 2007-06-08 | 2015-02-04 | 满康德股份有限公司 | IRE-1α抑制剂 |
| CN101906056B (zh) * | 2009-06-04 | 2013-10-30 | 中国科学院广州生物医药与健康研究院 | 作为m2抑制剂的环烷胺类化合物及其应用 |
| US8314250B2 (en) | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| FR3048698B1 (fr) * | 2016-03-11 | 2021-03-05 | Univ Claude Bernard Lyon | Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| PH12022550597A1 (en) | 2019-09-16 | 2024-03-04 | Takeda Pharmaceuticals Co | Azole-fused pyridazin-3(2h)-one derivatives |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015788A1 (en) * | 2001-07-20 | 2003-02-27 | Gemin X Biotechnologies Inc. | Methods for treatment of prevention of cancer or neoplastic diseases |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382213B1 (en) | 1989-02-08 | 1995-05-10 | Otsuka Pharmaceutical Co., Ltd. | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent |
| DK0730590T3 (da) | 1993-11-24 | 2001-03-19 | Du Pont Pharm Co | Isoxazolin og isozazol fibrinogenreceptorantagonister |
| US6693123B2 (en) * | 1995-11-06 | 2004-02-17 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| KR100399361B1 (ko) | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| EP1125925A1 (en) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| PT1268418E (pt) * | 2000-03-27 | 2006-08-31 | Applied Research Systems | Derivados da pirrolidina farmacologicamente activos com inibidores bax |
| AU2001284942A1 (en) | 2000-08-16 | 2002-02-25 | Georgetown University Medical Center | Small molecule inhibitors targeted at bcl-2 |
| US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US20040147473A1 (en) | 2000-11-10 | 2004-07-29 | Warrell Raymond P. | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US7855183B2 (en) | 2000-11-10 | 2010-12-21 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| ES2349349T3 (es) | 2001-05-30 | 2010-12-30 | The Regents Of The University Of Michigan | Asociacion sinergica de (-)-gosipol con docetaxel o paclitaxel para el tratamiento de cancer. |
| AU2003223708A1 (en) * | 2002-04-23 | 2003-11-10 | Axys Pharmaceuticals, Inc. | Novel phenyl derivatives as inducers of apoptosis |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| NZ539162A (en) * | 2002-09-04 | 2006-07-28 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| EP1581213A4 (en) * | 2002-12-18 | 2008-11-19 | Cytovia Inc | 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE |
| WO2004099158A1 (en) * | 2003-04-30 | 2004-11-18 | Ricerca Biosciences, Llc. | Monocyclic diazodioxide based bcl-2 protein antagonists |
| CA2526387A1 (en) * | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| AU2004272345A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| DE602004025504D1 (de) * | 2003-12-23 | 2010-03-25 | Novartis Ag | Bicyclische heterocyclische p-38-kinase-inhibitoren |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| PL1768966T3 (pl) | 2004-06-17 | 2012-08-31 | Infinity Discovery Inc | Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi |
| CN101014635A (zh) | 2004-08-30 | 2007-08-08 | 三菱丽阳株式会社 | 光学用共聚物及由其构成的成形体 |
| TW200626142A (en) * | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
-
2006
- 2006-11-30 TW TW095144471A patent/TWI403320B/zh not_active IP Right Cessation
- 2006-12-14 PE PE2006001602A patent/PE20071033A1/es not_active Application Discontinuation
- 2006-12-15 EP EP06845504.7A patent/EP1973875B1/en active Active
- 2006-12-15 SG SG201101864-5A patent/SG170727A1/en unknown
- 2006-12-15 KR KR1020087017168A patent/KR101373911B1/ko not_active Expired - Fee Related
- 2006-12-15 MY MYPI20082026A patent/MY153232A/en unknown
- 2006-12-15 CN CN2006800528798A patent/CN101374807B/zh not_active Expired - Fee Related
- 2006-12-15 AR ARP060105561A patent/AR058855A1/es unknown
- 2006-12-15 BR BRPI0619968-2A patent/BRPI0619968A2/pt not_active IP Right Cessation
- 2006-12-15 NZ NZ569660A patent/NZ569660A/en not_active IP Right Cessation
- 2006-12-15 WO PCT/US2006/047861 patent/WO2007075387A1/en not_active Ceased
- 2006-12-15 RU RU2008128569/04A patent/RU2424230C2/ru not_active IP Right Cessation
- 2006-12-15 US US11/640,480 patent/US7745464B2/en not_active Expired - Fee Related
- 2006-12-15 AU AU2006329879A patent/AU2006329879B2/en not_active Ceased
- 2006-12-15 MX MX2008007687A patent/MX2008007687A/es active IP Right Grant
- 2006-12-15 ES ES06845504.7T patent/ES2494765T3/es active Active
- 2006-12-15 JP JP2008545837A patent/JP5341521B2/ja not_active Expired - Fee Related
- 2006-12-15 CA CA2633958A patent/CA2633958C/en not_active Expired - Fee Related
- 2006-12-16 SA SA6270462A patent/SA06270462B1/ar unknown
- 2006-12-17 JO JO2006461A patent/JO2918B1/en active
-
2008
- 2008-06-10 IL IL192023A patent/IL192023A/en not_active IP Right Cessation
- 2008-06-13 TN TNP2008000258A patent/TNSN08258A1/en unknown
- 2008-07-03 ZA ZA200805822A patent/ZA200805822B/xx unknown
- 2008-07-04 MA MA31089A patent/MA30144B1/fr unknown
- 2008-07-07 NO NO20083050A patent/NO20083050L/no not_active Application Discontinuation
- 2008-07-07 EC EC2008008607A patent/ECSP088607A/es unknown
-
2010
- 2010-04-02 US US12/753,319 patent/US8304428B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015788A1 (en) * | 2001-07-20 | 2003-02-27 | Gemin X Biotechnologies Inc. | Methods for treatment of prevention of cancer or neoplastic diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI389895B (zh) | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 | |
| US8304428B2 (en) | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | |
| JPS63295588A (ja) | 生理活性物質ｋ−２５２の誘導体 | |
| KR20200038473A (ko) | 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체 | |
| CA3095415A1 (en) | Compound with anticancer activity | |
| JP2002510625A (ja) | Ｍｒｐ１の阻害方法 | |
| CN114390924A (zh) | 用于蛋白质降解的化合物、组合物和方法 | |
| KR20230118883A (ko) | Enpp1 억제제로서의 이미다졸 화합물 | |
| HK1119704B (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| HK1105963A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| HK1105963B (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131009 Termination date: 20161215 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |